ATE226092T1 - Thrombininhibitor-konjugate und endogene träger - Google Patents

Thrombininhibitor-konjugate und endogene träger

Info

Publication number
ATE226092T1
ATE226092T1 AT97937767T AT97937767T ATE226092T1 AT E226092 T1 ATE226092 T1 AT E226092T1 AT 97937767 T AT97937767 T AT 97937767T AT 97937767 T AT97937767 T AT 97937767T AT E226092 T1 ATE226092 T1 AT E226092T1
Authority
AT
Austria
Prior art keywords
thrombin
thrombin inhibitor
bloodstream
activity
compared
Prior art date
Application number
AT97937767T
Other languages
English (en)
Inventor
Alexander Krantz
Alan M Ezrin
Yonghong Song
Peter Milner
Dominique Bridon
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE226092T1 publication Critical patent/ATE226092T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97937767T 1996-07-01 1997-06-30 Thrombininhibitor-konjugate und endogene träger ATE226092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/674,315 US5840733A (en) 1996-07-01 1996-07-01 Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
PCT/IB1997/001093 WO1998000171A2 (en) 1996-07-01 1997-06-30 Conjugates of thrombin inhibitors and endogenes carriers

Publications (1)

Publication Number Publication Date
ATE226092T1 true ATE226092T1 (de) 2002-11-15

Family

ID=24706128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97937767T ATE226092T1 (de) 1996-07-01 1997-06-30 Thrombininhibitor-konjugate und endogene träger

Country Status (9)

Country Link
US (4) US5840733A (de)
EP (1) EP0956049B1 (de)
JP (1) JP2000514795A (de)
KR (1) KR20000022371A (de)
AT (1) ATE226092T1 (de)
CA (1) CA2258516A1 (de)
DE (1) DE69716474D1 (de)
IL (1) IL127712A0 (de)
WO (1) WO1998000171A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
DE69830305T2 (de) * 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
IL135835A0 (en) * 1997-11-07 2001-05-20 Conjuchem Inc Novel conjugates of opioids and endogenous carriers
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6440417B1 (en) * 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AU6937100A (en) * 1999-08-23 2001-03-19 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
EP1889639A3 (de) * 1999-09-07 2008-04-09 ConjuChem Biotechnologies Inc. Verfahren und Zusammensetzungen zur Herstellung antineoplastischer Wirkstoffe von hoher Haltbarkeit
CA2383798A1 (en) * 1999-09-07 2001-03-15 Conjuchem Inc. Pulmonary delivery for bioconjugation
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
EP1229924A4 (de) 1999-11-19 2004-12-15 Univ Leland Stanford Junior Gezielte bifunctionelle moleküle und darauf gegründete therapien
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
EP1980572A1 (de) * 2001-02-16 2008-10-15 ConjuChem Biotechnologies Inc. Glucagonartiges Peptid 2 (GLP-2) mit Langzeitwirkung für die Behandlung von Magendarmerkrankungen und -störungen
US6923939B1 (en) * 2001-07-05 2005-08-02 Uop Llc Heat activated membrane introduction apparatus and method for screening materials
PL371760A1 (en) * 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
JP2006514990A (ja) * 2002-12-27 2006-05-18 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物および方法
US7927579B2 (en) * 2003-01-17 2011-04-19 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2004103270A2 (en) * 2003-04-02 2004-12-02 Suntory Pharmaceutical Research Laboratories Llc Compounds and methods for treatment of thrombosis
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US20050181513A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by MAILDI mass spectrometry
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
CA2617920C (en) * 2005-09-01 2014-05-27 Baxter International Inc. Argatroban formulation comprising an acid as solubilizer
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
US8916148B2 (en) 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
HUE041305T2 (hu) 2008-02-08 2019-05-28 Red Hill Biopharma Ltd Gyulladásos bélbetegségek kezelésére alkalmazott módszerek és készítmények
US7915290B2 (en) * 2008-02-29 2011-03-29 Baxter International Inc. Argatroban formulations and methods for making and using same
US20090221637A1 (en) * 2008-02-29 2009-09-03 Baxter International Inc. Solid-state salt argatroban formulations and methods for producing and using the same
KR20140090663A (ko) 2011-11-07 2014-07-17 디아크론 파마슈티칼스, 인코포레이티드 직접 트롬빈 억제제의 연장 방출성 제형

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622615A (en) * 1968-11-06 1971-11-23 Parke Davis & Co N{11 -(p-tolylsulfonyl)-L-arginine esters
US4140681A (en) * 1974-11-08 1979-02-20 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4097591A (en) * 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4093712A (en) * 1974-11-08 1978-06-06 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073913A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4097472A (en) * 1974-11-08 1978-06-27 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4131673A (en) * 1974-11-08 1978-12-26 Mitsubishi Chemical Industries, Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US3978045A (en) * 1973-08-13 1976-08-31 Mitsubishi Chemical Industries Ltd. N2 -dansyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4133880A (en) * 1974-11-08 1979-01-09 Mitsubishi Chemical Industries Ltd. N2 -Substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US4069318A (en) * 1974-11-08 1978-01-17 Mitsubishi Chemical Industries Ltd. N2 -Alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4072743A (en) * 1974-11-08 1978-02-07 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4173630A (en) * 1974-11-08 1979-11-06 Mitsubishi Chemical Industries Limited N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4125619A (en) * 1974-11-08 1978-11-14 Mitsubishi Chemical Industries, Ltd. N2 -naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US4066773A (en) * 1974-11-08 1978-01-03 Mitsubishi Chemical Industries Ltd. N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4108986A (en) * 1974-11-08 1978-08-22 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4069323A (en) * 1974-11-08 1978-01-17 Mitsubishi Chemical Industries Ltd. N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4139529A (en) * 1974-11-08 1979-02-13 Mitsubishi Chemical Industries Limited N2 -Naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US4069329A (en) * 1974-11-08 1978-01-17 Mitsubishi Chemical Industries Limited N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4154828A (en) * 1974-11-08 1979-05-15 Mitsubishi Chemical Industries, Ltd. N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4073914A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4201863A (en) * 1974-11-08 1980-05-06 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4125604A (en) * 1974-11-08 1978-11-14 Mitsubishi Chemical Industries Limited N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073892A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4072757A (en) * 1974-11-08 1978-02-07 Mitsubishi Chemical Industries Limited N2 alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073891A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
NL7512637A (nl) * 1974-11-08 1976-05-11 Mitsubishi Chem Ind Werkwijze ter bereiding van een geneesmiddel, het aldus gevormde geneesmiddel en werkwijze voor de bereiding van actieve component.
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4066759A (en) * 1974-11-08 1978-01-03 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4046876A (en) * 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4072744A (en) * 1974-11-08 1978-02-07 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073916A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4168307A (en) * 1974-11-08 1979-09-18 Mitsubishi Chemical Industries Limited N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4117127A (en) * 1974-11-08 1978-09-26 Mitsubishi Chemical Industries Ltd. N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4101653A (en) * 1974-11-08 1978-07-18 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) * 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4069317A (en) * 1974-11-08 1978-01-17 Mitsubishi Chemical Industries Ltd. N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides
US4018913A (en) * 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4036955A (en) * 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4071621A (en) * 1976-01-14 1978-01-31 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
IE48623B1 (en) * 1978-08-31 1985-03-20 Mitsubishi Chem Ind Alpha-(n-arylsulfonyl-l-argininamides,processes for their preparation and pharmaceutical compositions containing these substances
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
SE8203887D0 (sv) * 1982-06-23 1982-06-23 Kabivitrum Ab Nya trombininhiberande foreningar
JPS61112018A (ja) * 1984-11-06 1986-05-30 Mitsubishi Chem Ind Ltd 線溶増強剤
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
ES2052517T3 (es) * 1986-07-16 1994-07-16 Eniricerche Spa Analogos de tuftsina parcialmente retroinversos, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
ATE124267T1 (de) * 1989-04-03 1995-07-15 Centocor Inc Blutplättchenspezifische immunokonjugate.
EP0422186B1 (de) * 1989-04-10 1998-12-09 Oncogen Limited Partnership Verwendung von oncostatin m zur suppression von mhc antigenen
EP0395918A3 (de) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen-Aktivatorkomplex von reiner Pro-Urokinase, kovalent gebunden durch eine Disulfidbrücke an menschlichem Serumalbumin
US5240913A (en) * 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5122615A (en) * 1990-12-11 1992-06-16 American Cyanamid Company Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds
DE4111394A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
US5458568A (en) * 1991-05-24 1995-10-17 Cortrak Medical, Inc. Porous balloon for selective dilatation and drug delivery
CA2074304C (en) * 1991-08-02 1996-11-26 Cyril J. Schweich, Jr. Drug delivery catheter
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
TW223629B (de) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5506241A (en) * 1992-03-18 1996-04-09 Mitsubishi Chemical Corporation Argatroban preparations for ophthalmic use
FR2689130B1 (fr) * 1992-03-30 1994-05-27 Synthelabo Derives de 1-[2 (arylsulfonylamino)ethyl-1-oxo] piperidine, leur preparation et leur application en therapeutique.
US5371091A (en) * 1992-08-31 1994-12-06 Bristol-Myers Squibb Company Heteroaromatic amine thrombin inhibitors
FR2695562B1 (fr) * 1992-09-11 1994-10-14 Synthelabo Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5332822A (en) * 1992-12-24 1994-07-26 Bristol-Myers Squibb Company Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors
JPH06219949A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
JPH06219948A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
WO1994017817A1 (en) * 1993-02-12 1994-08-18 Corvas International, Inc. Inhibitors of thrombosis
AU5495194A (en) * 1993-02-26 1994-09-01 Becton Dickinson & Company Flow through membrane nucleic acid hybridization assay
FR2702220B1 (fr) * 1993-03-03 1995-05-12 Synthelabo Dédoublement enzymatique de dérivés de 4-alkyl-2-pipéridine-carboxylate et utilisation des composés obtenus, comme intermédiaires de synthèse.
ATE177635T1 (de) * 1993-04-22 1999-04-15 Senju Pharma Co Wässrige arzneizubereitungen enthaltend argatroban und cyclodextrin oder coffein
FR2710061B1 (fr) * 1993-09-14 1995-12-29 Synthelabo Acides et chlorures d'acides 1,2,3, 4-tétrahydroquinoléine-8-sulfoniques, et leur utilisation comme intermédiaires de synthèse.
DE4342154A1 (de) * 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
FR2715566B1 (fr) * 1994-02-03 1996-03-08 Synthelabo Solutions aqueuses concentrées d'argatroban.
US5484772A (en) * 1994-03-04 1996-01-16 Eli Lilly And Company Antithrombotic agents
US5488037A (en) * 1994-03-04 1996-01-30 Eli Lilly And Company Antithrombotic agents
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5588962A (en) * 1994-03-29 1996-12-31 Boston Scientific Corporation Drug treatment of diseased sites deep within the body
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
US5637599A (en) * 1994-06-17 1997-06-10 Corvas International, Inc. Arginine mimic derivatives as enzyme inhibitors
DE4424828A1 (de) * 1994-07-14 1996-01-18 Thomae Gmbh Dr K Neue substituierte Arylsulfonamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US5626562A (en) * 1994-11-28 1997-05-06 Devices For Vascular Intervention Drug delivery catheter
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5612378A (en) * 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
US5559150A (en) * 1995-06-06 1996-09-24 3-Dimensional Pharmaceuticals, Inc. N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors
US5713853A (en) * 1995-06-07 1998-02-03 Interventional Innovations Corporation Methods for treating thrombosis
US5612369A (en) * 1995-06-07 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Thrombin inhibitors
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
JP2000514795A (ja) 2000-11-07
US5942620A (en) 1999-08-24
KR20000022371A (ko) 2000-04-25
AU715746B2 (en) 2000-02-10
EP0956049A2 (de) 1999-11-17
US6277863B1 (en) 2001-08-21
CA2258516A1 (en) 1998-01-08
EP0956049B1 (de) 2002-10-16
AU4028397A (en) 1998-01-21
IL127712A0 (en) 1999-10-28
WO1998000171A3 (en) 1998-06-04
US5840733A (en) 1998-11-24
US6087375A (en) 2000-07-11
WO1998000171A2 (en) 1998-01-08
DE69716474D1 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
ATE226092T1 (de) Thrombininhibitor-konjugate und endogene träger
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
MY106598A (en) Compositions and methods for drug delivery and chromatography.
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
CY1116124T1 (el) Χρησεις αντισωματων για αμινοφωσφολιπιδια για τη θεραπευτικη αγωγη καρκινου
DE60041138D1 (de) Hochvisköse embolisierende mittel
ATE252601T1 (de) Lang wirkende insulinotrope peptide
ATE244579T1 (de) Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
BR9912327A (pt) Inibidores da uroquinase
NO960226D0 (no) Anti-angiogene blandinger og fremgangsmåter for anvendelse
MXPA04004026A (es) Conjugados polimericos de inhibidores de la proteina quinasa c.
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
TR200001954T2 (tr) Faktör XA'nın önleyicileri olarak indol türevleri.
BR0014378A (pt) Derivados de ácido indolil-3-glioxìlico tendo propriedades terapeuticamente valiosas
EA200401622A1 (ru) Способы лечения ангиогенеза, роста опухолей и метастазов
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
EP1666469A4 (de) Inhibitor des plasminogenaktivatorinhibitors-1
US20020155999A1 (en) Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
ATE317703T1 (de) Polymer-wirkstoff-konjugate zur behandlung von krebs
DE69329062D1 (de) Verwendung von inhibitoren der 3-hydroxy-3-methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie
ATE339202T1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
Maison et al. Improved chemical strategies for the targeted therapy of cancer
Harding et al. Interaction of the antitumor antibiotic streptonigrin with metal ions and DNA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties